Provided herein are methods of screening for ADAR1 inhibitors, and compounds identified by the method. In certain embodiments, the methods include treating with an inhibitor of ADAR1.

Provided herein are methods of screening for ADAR1 inhibitors, and compounds identified by the method. In certain embodiments, the methods include treating with an inhibitor of ADAR1.

Provided herein are methods of screening for ADAR1 inhibitors, and compounds identified by the method. In certain embodiments, the methods include treating with an inhibitor of ADAR1.

A compound according to formula (I) ##STR00001##
wherein: is a phenyl ring, a C.sub.4 to C.sub.9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group;
which shows high affinity for muscarinic M.sub.3 receptors (Hm3).

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.

Disclosed herein, are synergistic compositions comprising a nitroimidazole compound, a nitrofuran compound, or an anti-tumor agent; and a low minimum inhibitory concentration antibiotic, and methods of treating, preventing or inhibiting a facultative anaerobe infection by administering the compositions to a subject.

Disclosed herein, are synergistic compositions comprising a nitroimidazole compound, a nitrofuran compound, or an anti-tumor agent; and a low minimum inhibitory concentration antibiotic, and methods of treating, preventing or inhibiting a facultative anaerobe infection by administering the compositions to a subject.

The instant disclosure relates to methods which employ the detection of ADP-D-glycero--D-manno-heptose (ADP-heptose) in a biological sample obtained from an individual. In certain aspects, the methods comprise administering a treatment to an individual in which ADP-heptose is detected. The methods may further comprise determining whether the individual has clonal hematopoiesis of indeterminate potential (CHIP) and circulating ADP-heptose.

The instant disclosure relates to methods which employ the detection of ADP-D-glycero--D-manno-heptose (ADP-heptose) in a biological sample obtained from an individual. In certain aspects, the methods comprise administering a treatment to an individual in which ADP-heptose is detected. The methods may further comprise determining whether the individual has clonal hematopoiesis of indeterminate potential (CHIP) and circulating ADP-heptose.